SIRT1 Emerges as a Plausible Molecular Link Between Bone Marrow Edema and Bone Remodeling

Bone marrow edema, the painful fluid-like signal that lights up fluid-sensitive MRI sequences inside bone, has long been treated as a radiological curiosity rather than a molecularly defined disease. A new review published in Immunity, Inflammation and Disease now argues that a single, well-studied enzyme may sit at the crossroads between this mysterious condition and the continuous process of bone renewal. The molecule in question is SIRT1, a NAD+-dependent deacetylase famous for its roles in aging, metabolism, and inflammation. The authors, led by Yiming Chen and Yuanyi Tang, synthesize evidence from cell biology, animal models, and imaging studies to build a working model in which declining SIRT1 activity could help create the marrow conditions that favor edema, while simultaneously undermining the bone remodeling machinery needed to repair it.

SIRT1 is one of seven mammalian sirtuins, enzymes that remove acetyl groups from histones and transcription factors in a reaction that consumes NAD+, a molecule whose abundance tracks the metabolic state of the cell. By deacetylating regulators such as FOXO, p53, and NF-κB, SIRT1 influences cell survival, senescence, mitochondrial biogenesis, and inflammatory tone. In bone, these capabilities translate into a remarkably broad portfolio. The enzyme promotes the differentiation of mesenchymal stem cells into bone-forming osteoblasts, restrains the bone-resorbing osteoclasts, and fine-tunes the signaling of osteocytes, the embedded cells that sense mechanical load and orchestrate remodeling. Because SIRT1 activity declines with age and metabolic disease, researchers have increasingly suspected that its loss contributes to osteoporosis, marrow fat accumulation, and impaired fracture repair.

The review details how SIRT1 acts on each arm of bone remodeling. In the osteoblast lineage, SIRT1 deacetylates and activates RUNX2, the master transcription factor of bone formation, and promotes the nuclear translocation of Bmi1, a polycomb protein that supports stem cell self-renewal and osteoblastic commitment. In osteoclast precursors, SIRT1 deacetylates the p65/RelA subunit of NF-κB, blunting the RANKL-driven program that produces bone-resorbing cells. In osteocytes, a CK2–USP4–SIRT1 axis stabilizes the enzyme and represses the Sost gene, lowering sclerostin output and thereby releasing the brakes on WNT/β-catenin signaling in osteoblasts. The enzyme also supports osteoblast glycolysis through regulation of GOT1, linking cellular energy metabolism directly to the bioenergetic demands of matrix synthesis and mineralization.

Bone marrow edema, by contrast, is not a single process but a spectrum. On MRI it appears as low signal on T1-weighted images and high signal on T2-weighted or STIR sequences, but the underlying histology can include interstitial fluid accumulation, fibrosis, microvascular proliferation, inflammatory infiltrates, or trabecular microdamage. The review identifies four interlocking mechanisms: vascular leakage driven by capillary dysfunction and venous congestion; microfractures from trauma or mechanical overload; inflammation that raises vascular permeability and recruits immune cells; and metabolic disturbances including hypoxia, oxidative stress, and expanded marrow fat. Rising intraosseous pressure from fluid accumulation irritates nerve endings, impairs perfusion, and produces the characteristic pain. Clinically, edema matters because it predicts cartilage wear in osteoarthritis, structural progression in inflammatory arthritis, and, in pre-collapse avascular necrosis of the femoral head, is associated with oxidative stress, fibrosis, and elevated osteoclast activity.

The critical insight of the new synthesis is that SIRT1 touches nearly every one of these mechanisms. Where direct lesion-level data are lacking, the authors assemble converging indirect evidence. SIRT1 governs the fate of bone marrow mesenchymal stem cells: when its activity falls, lineage commitment shifts away from osteogenesis and toward adipogenesis, expanding bone marrow adipose tissue. Marrow fat, in turn, is mechanistically linked to edema because it compresses vascular spaces, impairs perfusion, and secretes adipokines with proinflammatory and anti-osteogenic effects. In mouse models of chronic energy deficit, SIRT1 deficiency produces increased marrow adiposity and bone loss, and the SIRT1 activator resveratrol partially rescues these phenotypes, tying energy state, enzyme activity, and marrow composition into a single pathway.

Vascular biology offers another plausible route. SIRT1 deacetylates endothelial nitric oxide synthase, boosting nitric oxide production that maintains vasodilation and limits permeability. Loss of SIRT1 activity in mice degrades the endothelial glycocalyx, the protective proteoglycan layer lining blood vessels, while elevating superoxide production and acetylated NF-κB/p65, changes that favor capillary leakage. In bone marrow endothelial cells specifically, erythropoietin has been shown to induce nuclear translocation of SIRT1, preserving endothelial integrity through mitochondrial health. Because vascular leakage is a hallmark of marrow edema, these findings suggest that diminished SIRT1 could directly weaken the barrier that keeps fluid inside vessels.

Inflammation and oxidative stress provide a third axis. SIRT1 suppresses transcription of IL-1β, IL-6, and TNF-α by deacetylating NF-κB components, and it enhances antioxidant defenses through Nrf2, PGC-1α, and FOXO transcription factors, raising enzymes such as SOD, catalase, and HO-1. In mesenchymal stem cells, the microRNA miR-128-3p reduces SIRT1 expression and thereby increases inflammatory mediators, an effect that resveratrol can ameliorate. The enzyme also intersects with hypoxia signaling, regulating HIF-1α stability and potentially modulating VEGF-driven angiogenesis and permeability in the poorly perfused, high-pressure marrow regions where edema develops. Metabolic resilience completes the picture: SIRT1 supports mitochondrial biogenesis, glycolytic flexibility, AMPK activation, and autophagy, all of which help marrow stromal and endothelial cells maintain ion gradients and fluid homeostasis under stress.

The authors are careful to flag the limits of this framework. No published study has yet measured SIRT1 expression or enzymatic activity inside human or animal edema lesions, and causality remains unproven: altered SIRT1 could be a downstream consequence of hypoxia and inflammation rather than the initiating driver. The energy-deficit models that dominate the literature capture chronic metabolic stress but do not reproduce the acute vascular leakage and trauma-related microdamage typical of many clinical edema syndromes. Human data correlating marrow SIRT1 activity with edema severity on MRI are essentially absent. The review also notes that BME etiologies are heterogeneous, spanning trauma, osteoarthritis, ischemia, and inflammatory disease, so SIRT1’s relevance may vary by context.

Therapeutically, the stakes are considerable. Resveratrol improves trabecular bone structure in ovariectomized rodents and increases SIRT1 expression in mesenchymal stem cells from patients with type 2 diabetes, while NAD+ precursors such as nicotinamide mononucleotide and nicotinamide riboside improve endothelial function and reduce oxidative stress in other tissues. Combination strategies pairing SIRT1 activators with anti-inflammatory cytokine inhibitors or vascular-stabilizing agents have shown additive protection in analogous models, though none has been tested in edema specifically. Caution is warranted: high-dose resveratrol has in some settings reduced trabecular bone volume or increased resorption markers, resveratrol’s poor bioavailability demands novel delivery systems such as nanoparticles or bone-targeting conjugates, and systemic SIRT1 activation carries off-target risks. Spectral computed tomography, with virtual non-calcium imaging achieving sensitivities of roughly 86 to 94 percent, may soon make edema quantification faster and more accessible than MRI, opening the door to imaging-molecular correlation studies.

The review closes with a research roadmap: biopsy MRI-confirmed edema lesions to quantify SIRT1 activity; build animal models that faithfully reproduce vascular and inflammatory edema and manipulate Sirt1 genetically; run longitudinal imaging time courses to determine whether early activation prevents edema or later activation accelerates resolution; and dissect how sclerostin upregulation, marrow fat expansion, and altered stem cell metabolism converge to raise intraosseous pressure. Until those experiments are done, SIRT1 remains what the authors call a biologically plausible but unvalidated mediator, a promising molecular handle on a condition that has so far been defined only by what it looks like on a scan.

Subject of Research: The role of the NAD+-dependent deacetylase SIRT1 in bone marrow edema and bone remodeling

Article Title: The Role of SIRT1 in Mediating Bone Marrow Edema and Its Interface With Bone Remodeling

Article References: Chen, Y., Li, X., Zheng, Z., Liu, Z., Xu, T., & Tang, Y. (2026). The Role of SIRT1 in Mediating Bone Marrow Edema and Its Interface With Bone Remodeling. Immunity, Inflammation and Disease, 14(9), Article e70505. https://doi.org/10.1002/iid3.70505

Image Credits: AI Generated

DOI: 10.1002/iid3.70505

Keywords: SIRT1, bone marrow edema, bone remodeling, osteoblasts, osteoclasts, mesenchymal stem cells, marrow adiposity, NF-kB, oxidative stress, vascular permeability, resveratrol, MRI